Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine Region

Background: The primary objective of this work was to assess the prevalence and distribution of HPV genotypes in immunosuppressed patients, and to compare them with the French Monsonego cohort. Secondary objectives were to evaluate whether the risk of HPV infection was correlated with HIV viral load...

Full description

Bibliographic Details
Main Authors: Margot Boudes, Véronique Venard, Thierry Routiot, Marie Buzzi, Floriane Maillot
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Viruses
Subjects:
Online Access:https://www.mdpi.com/1999-4915/13/12/2454
_version_ 1797499896384716800
author Margot Boudes
Véronique Venard
Thierry Routiot
Marie Buzzi
Floriane Maillot
author_facet Margot Boudes
Véronique Venard
Thierry Routiot
Marie Buzzi
Floriane Maillot
author_sort Margot Boudes
collection DOAJ
description Background: The primary objective of this work was to assess the prevalence and distribution of HPV genotypes in immunosuppressed patients, and to compare them with the French Monsonego cohort. Secondary objectives were to evaluate whether the risk of HPV infection was correlated with HIV viral load, CD4 cell count in HIV-infected patients and the type, number of immunosuppressive therapies or type of pathology (transplant vs. autoimmune diseases) in patients undergoing long-term immunosuppressive therapy. Methods: An observational, monocentric and historical study was conducted including all immunosuppressed patients having received an HPV testing, in the Laboratory of Virology, Nancy Regional Teaching Hospital Center, between 2014 and 2020. Immunosuppressed patients were either HIV-infected or received long-term immunosuppressive therapy. Results: In our cohort, the prevalence of HPV infection (75.6% vs. 16.1% <i>p</i> < 0.05), the proportion of patients with high-risk HPV infection (48.9% vs. 15.1% <i>p</i> < 0.05) and with multiple HPV infection (41.1% vs. 5.7% <i>p</i> < 0.05) were significantly higher than in the Monsonego cohort. HPV 52 (13%), 53 (13%) and 16 (10%) were the most common in the immunosuppressed population, while it was HPV 16, 42 and 51 in the Monsonego cohort. Conclusions: This study supports that a particular attention must be given to all the immunosuppressed patients for the screening and care of HPV-related diseases because of major modifications of HPV epidemiology compared with the overall population.
first_indexed 2024-03-10T03:54:01Z
format Article
id doaj.art-48b551fd7bc74e01be872a6a9ef7f202
institution Directory Open Access Journal
issn 1999-4915
language English
last_indexed 2024-03-10T03:54:01Z
publishDate 2021-12-01
publisher MDPI AG
record_format Article
series Viruses
spelling doaj.art-48b551fd7bc74e01be872a6a9ef7f2022023-11-23T10:58:10ZengMDPI AGViruses1999-49152021-12-011312245410.3390/v13122454Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine RegionMargot Boudes0Véronique Venard1Thierry Routiot2Marie Buzzi3Floriane Maillot4Department of Medical Gynecology, CHRU Nancy, 10 rue Heydenreich, 54000 Nancy, FranceFaculty of Medicine, University of Lorraine, 9 Avenue de la Forêt de Haye, 54505 Nancy, FranceDepartment of Obstetrics & Gynecology, CHRU Nancy, 10 rue Heydenreich, 54000 Nancy, FranceFaculty of Medicine, University of Lorraine, 9 Avenue de la Forêt de Haye, 54505 Nancy, FranceDepartment of Medical Gynecology, CHRU Nancy, 10 rue Heydenreich, 54000 Nancy, FranceBackground: The primary objective of this work was to assess the prevalence and distribution of HPV genotypes in immunosuppressed patients, and to compare them with the French Monsonego cohort. Secondary objectives were to evaluate whether the risk of HPV infection was correlated with HIV viral load, CD4 cell count in HIV-infected patients and the type, number of immunosuppressive therapies or type of pathology (transplant vs. autoimmune diseases) in patients undergoing long-term immunosuppressive therapy. Methods: An observational, monocentric and historical study was conducted including all immunosuppressed patients having received an HPV testing, in the Laboratory of Virology, Nancy Regional Teaching Hospital Center, between 2014 and 2020. Immunosuppressed patients were either HIV-infected or received long-term immunosuppressive therapy. Results: In our cohort, the prevalence of HPV infection (75.6% vs. 16.1% <i>p</i> < 0.05), the proportion of patients with high-risk HPV infection (48.9% vs. 15.1% <i>p</i> < 0.05) and with multiple HPV infection (41.1% vs. 5.7% <i>p</i> < 0.05) were significantly higher than in the Monsonego cohort. HPV 52 (13%), 53 (13%) and 16 (10%) were the most common in the immunosuppressed population, while it was HPV 16, 42 and 51 in the Monsonego cohort. Conclusions: This study supports that a particular attention must be given to all the immunosuppressed patients for the screening and care of HPV-related diseases because of major modifications of HPV epidemiology compared with the overall population.https://www.mdpi.com/1999-4915/13/12/2454human papillomavirusHPV genotypesimmunosuppressed patientsHIVimmunosuppressive therapy
spellingShingle Margot Boudes
Véronique Venard
Thierry Routiot
Marie Buzzi
Floriane Maillot
Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine Region
Viruses
human papillomavirus
HPV genotypes
immunosuppressed patients
HIV
immunosuppressive therapy
title Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine Region
title_full Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine Region
title_fullStr Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine Region
title_full_unstemmed Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine Region
title_short Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine Region
title_sort prevalence and distribution of hpv genotypes in immunosuppressed patients in lorraine region
topic human papillomavirus
HPV genotypes
immunosuppressed patients
HIV
immunosuppressive therapy
url https://www.mdpi.com/1999-4915/13/12/2454
work_keys_str_mv AT margotboudes prevalenceanddistributionofhpvgenotypesinimmunosuppressedpatientsinlorraineregion
AT veroniquevenard prevalenceanddistributionofhpvgenotypesinimmunosuppressedpatientsinlorraineregion
AT thierryroutiot prevalenceanddistributionofhpvgenotypesinimmunosuppressedpatientsinlorraineregion
AT mariebuzzi prevalenceanddistributionofhpvgenotypesinimmunosuppressedpatientsinlorraineregion
AT florianemaillot prevalenceanddistributionofhpvgenotypesinimmunosuppressedpatientsinlorraineregion